GlassScriptPhysician profile
Kendal Lilly
NPI 1598474520
$4,208.81
in general payments reported to CMS, 2019-2025
30 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what 94% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $67.48 · 2023: $1,215 · 2024: $1,240 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,141.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,155.83 | 2022-2025 | |
| Novo Nordisk INC | $466.11 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $403.90 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $315.31 | 2023-2025 | Caplyta |
| Pfizer INC. | $260.19 | 2023-2025 | |
| Lilly USA, LLC | $243.12 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Otsuka America Pharmaceutical, INC. | $167.40 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $109.21 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $107.94 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $106.41 | 2024-2025 | Spravato |
| Axsome Therapeutics, INC. | $102.46 | 2024-2025 | Auvelity, Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.94 | 2023-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $98.33 | 2024-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $89.96 | 2024-2025 | Voquezna |
| Radius Health, INC. | $83.92 | 2024-2025 | Tymlos |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $70.03 | 2024-2025 | Opsumit, Uptravi |
| Amgen INC. | $49.80 | 2023 | Repatha, Otezla |
| Abbott Laboratories | $35.83 | 2025 | Freestyle Libre 3 |
| Harmony Biosciences LLC | $32.88 | 2023-2024 | Wakix |
| Teva Pharmaceuticals USA, INC. | $32.42 | 2023 | Austedo Xr, Ajovy |
| Xeris Pharmaceuticals, INC. | $27.42 | 2024 | Gvoke Hypopen |
| Shield Therapeutics INC | $22.07 | 2025 | |
| Dexcom, INC. | $18.70 | 2023 | Dexcom G6 Transmitter |
| Biomarin Pharmaceutical INC. | $18.03 | 2024 | Voxzogo 1.2mg |
| Phadia US INC. | $16.55 | 2023 | Immunocap |
| Avadel Cns Pharmaceuticals, LLC | $16.37 | 2025 | Lumryz |
| Corcept Therapeutics | $15.98 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.48 | 2022 | |
| Athena Bioscience, LLC | $14.30 | 2023 | Nexiclon Xr |
| Astellas Pharma US INC | $12.92 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendal Lilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.